Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Heron Therapeutics and keeping the price target at $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight the promising future of Heron Therapeutics. The company’s recent third-quarter earnings report indicates positive momentum for their key products, Zynrelef and Aponvie, which are entering a critical phase of commercial growth. The introduction of a permanent J-code for Zynrelef simplifies reimbursement processes, potentially boosting its adoption and sales.
Additionally, Zynrelef’s demand has shown significant year-over-year growth, supported by strategic initiatives such as enhanced distributor incentives and the establishment of a new peri-operative clinical educator team. Aponvie has also demonstrated impressive sales growth, aided by the formation of a dedicated sales team. These developments, along with stable Cinvanti revenues, suggest a strong trajectory for Heron Therapeutics, justifying the Buy rating.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HRTX in relation to earlier this year.